Indivior PLC CFO Departs, Interim Appointed
Ticker: INDV · Form: 8-K · Filed: Mar 4, 2025 · CIK: 1625297
Sentiment: neutral
Topics: management-change, cfo-departure
TL;DR
Indivior's CFO is out, interim steps in. Watch this space.
AI Summary
On March 2, 2025, Indivior PLC announced the departure of its Chief Financial Officer, Ryan Wm. Tomczyk, effective March 15, 2025. The company also announced the appointment of Mark W. Smith as interim CFO. Indivior PLC is a pharmaceutical company specializing in addiction treatment.
Why It Matters
A change in CFO can impact investor confidence and financial strategy. The market will be watching to see how the interim CFO manages the company's finances.
Risk Assessment
Risk Level: medium — A CFO departure, especially without a permanent replacement named, introduces uncertainty regarding financial leadership and strategy.
Key Players & Entities
- Indivior PLC (company) — Registrant
- Ryan Wm. Tomczyk (person) — Departing Chief Financial Officer
- March 15, 2025 (date) — Effective date of CFO departure
- Mark W. Smith (person) — Appointed Interim Chief Financial Officer
- March 2, 2025 (date) — Date of report
FAQ
Who is the departing Chief Financial Officer of Indivior PLC?
Ryan Wm. Tomczyk is the departing Chief Financial Officer of Indivior PLC.
When is Ryan Wm. Tomczyk's departure effective?
Ryan Wm. Tomczyk's departure is effective March 15, 2025.
Who has been appointed as the interim Chief Financial Officer?
Mark W. Smith has been appointed as the interim Chief Financial Officer.
What is the date of this Form 8-K filing?
The date of this Form 8-K filing is March 2, 2025.
What is Indivior PLC's primary business?
Indivior PLC is primarily involved in pharmaceutical preparations, specifically in the area of addiction treatment.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 4, 2025 by Ryan Wm. Tomczyk regarding INDIVIOR PLC (INDV).